La chaîne d'options affiche les données clés des options sur actions de Soligenix à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Soligenix..

Soligenix (NASDAQ:SNGX) Stock, Chaîne d'Options

Soligenix

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Soligenix Inc

Press Releases

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

News

Synergy Corp. (NASDAQ: SNYR) 1,600+ Nationwide Store Rollout – PPCB, SNGX, BTAI, HIT + Other Disruptive Stocks Moving Now!

Small Cap

Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses

Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Penny Stocks

Offerings

Soligenix Announces Pricing of $7.5 Million Public Offering

Soligenix Announces Closing of $7.5 Million Public Offering

Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

AMZN

BTAI

COST

PPCB

SNGX

SNYR

VTAK

Abpro Hldgs

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

Aptorum Group Limited - Class A Ordinary Shares

Aptorum Group

BioCardia

bioAffinity Technologies, Inc. - Common Stock

bioAffinity Technologies

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Edesa Biotech

Ernexa Therapeutics

Evogene

Imunon

Immuron Limited - American Depositary Shares

Immuron

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Mustang Bio

Marker Therapeutics

OSR Holdings

BiomX

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Silexion Therapeutics Corp - Ordinary Shares

Silexion Therapeutics

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Alliance Global Partners

Screenshot 2025-05-02 at 5.43.08 PM

Biotech

Soligenix Issues Interim Results For CTCL Treatment Trial – 75% Response At 18 Weeks, 3 Patients Achieve Complete Response

Screenshot 2025-04-23 at 10.53.10 PM

General

Soligenix&#39;s HyBryte™ Shows 75% Response Rate In Skin Cancer Trial, Backed By FDA Funding

Screenshot 2025-02-24 at 11.30.54 PM

Interview

Soligenix Aims To Push The Boundaries In Treating Rare Diseases

Screenshot 2025-02-20 at 6.32.00 PM

Soligenix&#39;s Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And 2026

Screenshot 2025-02-18 at 6.39.51 PM

Improving Patient Quality Of Life: Soligenix Progresses Treatment For Painful Ulcers Associated With Rare Behçet&#39;s Disease

Screenshot 2025-01-16 at 7.00.06 PM

Soligenix Targets Psoriasis With New Therapy

Screenshot 2024-12-16 at 6.43.37 PM

Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL

Screenshot 2024-11-26 at 8.32.36 PM

Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs

Comments

Soligenix

Soligenix (SNGX) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL